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Letter to the Editor
HUMAN PAPILLOMAVIRUS VACCINE FOR CERVICAL
CANCER: WHERE ARE WE NOW?
To the Editor:
I read with interest the review article by Cheng [1]. In the introduction section of the article, the author
cites that cervical cancer kills around 250,000 women every year worldwide. In the section on the
prevalence and incidence of cervical cancer, however, “Approximately 500,000 women worldwide
develop cervical cancer yearly, resulting in about 200,000 cervical cancer deaths each year (estimated in
the year 1995)”. The author omits to mention the difference of 50,000 deaths a year worldwide, which
is potentially puzzling.
Regarding the last paragraph in the section on HPV infection and cervical cancer, “Retrospective
studies on archival Papanicolaou (Pap) cervical smear samples have successfully documented the
existence of HPV exposure decades before the development of the disease, and have shown relative risk
estimates for HPV positivity and invasive cervical cancer of 16.4 and 32, respectively (reference 88).” I do
not really know what that means.
Firstly, in a retrospective case-control study, there are no relative risk ratios but odds ratios (ORs). ORs
and their confidence intervals (CIs) are estimated by logistic regression analysis [2]. Secondly, I have
reviewed reference 88; the authors presented the results of their retrospective case-control study using
archival smears of women who developed cervical cancer in Zeeland, The Netherlands [2]. A total of 57
case women and a total of 202 smears before cancer diagnosis were studied. They investigated high-risk
HPV DNA presence by general primer GP5+/6+ polymerase chain reaction. Also, the normal cervical
smears of 114 age-matched control women were analyzed. High-risk HPV DNA was detected in 37 of the
57 (65%) baseline smears of the case women, and in 7 of the 114 (6%) smears of the control women (OR,
28; 95% CI, 11–72). I do not know if it was cited wrongly as 16.4. Thirdly, in 7 of 10 (70%) undisputable
normal baseline smears, high-risk HPV positivity was revealed after revision, whereas only 7 of 104 (7%)
revised normal smears of the control women were HPV positive (OR, 32; 95% CI, 6.8–153). In other
words, the crude OR for high-risk HPV detection in revised baseline smears to predict the development
of carcinoma was 32 (95% CI, 6.8–153). Finally, the median duration to diagnosis of cervical cancer for
the HPV positive revised baseline smears was 10.7 years (range, 9.6–17.4 years). This was not markedly
different from the revised baseline smears that were HPV negative (10.7 years; range, 8.6–15.2 years) in
the original article. I do not appreciate the existence of HPV exposure “decades” before the development
of the disease.
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